U.S. License Holder:
Ferring
Date of License:
January-15-1974
Last Update:
Sep-30-2024
FDA-Approved Indications
NOVAREL (chorionic gonadotropin) is indicated for:
Prepubertal cryptorchidism not due to anatomical obstruction;
Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males;
Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.